| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
HLS Stock Overview
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia.
Healius Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.36 |
| 52 Week High | AU$5.54 |
| 52 Week Low | AU$3.36 |
| Beta | 1.1 |
| 1 Month Change | -11.58% |
| 3 Month Change | -9.92% |
| 1 Year Change | -31.85% |
| 3 Year Change | 4.35% |
| 5 Year Change | 9.09% |
| Change since IPO | 140.00% |
Recent News & Updates
Shareholder Returns
| HLS | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -2.9% | -4.6% | -2.7% |
| 1Y | -31.8% | -20.7% | -11.0% |
Return vs Industry: HLS underperformed the Australian Healthcare industry which returned -20.7% over the past year.
Return vs Market: HLS underperformed the Australian Market which returned -11% over the past year.
Price Volatility
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 3.6% |
| Healthcare Industry Average Movement | 5.2% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 4.3% |
Stable Share Price: HLS is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HLS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 11,000 | Malcolm Parmenter | https://www.healius.com.au |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.
Healius Limited Fundamentals Summary
| HLS fundamental statistics | |
|---|---|
| Market Cap | AU$1.92b |
| Earnings (TTM) | AU$294.00m |
| Revenue (TTM) | AU$2.34b |
6.5x
P/E Ratio0.8x
P/S RatioIs HLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLS income statement (TTM) | |
|---|---|
| Revenue | AU$2.34b |
| Cost of Revenue | AU$1.33b |
| Gross Profit | AU$1.00b |
| Other Expenses | AU$710.50m |
| Earnings | AU$294.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.51 |
| Gross Margin | 42.99% |
| Net Profit Margin | 12.58% |
| Debt/Equity Ratio | 31.5% |
How did HLS perform over the long term?
See historical performance and comparison